Forschung Pankreaszentrum

Welcome to the Website of the Pancreatic Neuropathy and Pain Research Group. We belong to the Department of Surgery at the Technical University of Munich


As clinician-scientists, we perform both basic science and clinical research for elucidating the clinically relevant aspects of human pancreatic cancer and chronic pancreatitis. Our research integrates molecular biology with in-depth characterization of human pancreatic tissue, advanced 3D heterotypic cultures models, live cell imaging, genetically engineered mouse models (GEMMs) of pancreatic cancer, and mouse models of acute and chronic pancreatitis. We are part of the Collaborative Research Centre 1321 (Modelling and Targeting of Pancreatic Cancer), of the DKTK (German Cancer Consortium) Munich site, and of the Pancreatic Cancer Alliance Munich (PCAM).

Importantly, we derive our research questions and objectives directly from the human tissue and human disease, and aim at developing in vitro and in vivo models that best mimic the human conditions. Our research group is an international team of biologists and clinicians with the aim to uncover selected disease mechanisms in pancreatic disease with the ultimate goal of developing novel therapy strategies.
The main three lines of investigation in our laboratory are as follows:


1) Mechanisms of neural invasion and neuropathy in human pancreatic Cancer Co-Investigators: Istvanffy, Wang
Neural invasion is one of hallmarks of human pancreatic cancer and pancreatic neuropathy, and it drastically worsens the prognosis of patients due to early recurrence. We developed novel research tools for simulating neural invasion in 3D culture and, together with our collaboration partners, characterized novel GEMMs of pancreatic cancer that exhibit human-like neural invasion. We currently focus on the role of Schwann cells, stromal cells (i.e. cancer-associate fibroblasts), mesenchymal stem cells, and especially immune cells as potential inducers of neural invasion.

2) Tumor immune profile in locally advanced and resectable pancreatic Cancer
Co-Investigators: Istvanffy, Safak, Mota-Reyes
Neoadjuvant therapy has remarkably improved the prognosis of patients with locally advanced pancreatic cancer, who can in ca. 60% of cases become candidates for surgical resection after tumor downsizing. We are applying novel mouse models that allow the application of neoadjuvant therapy similar to the clinical setting, and analyse the immune profile of neoadjuvantly treated versus primary resected pancreatic cancer in simultaneous comparison with human specimens.

3) Pain mechanisms in pancreatitis and pancreatic Cancer
Co-Investigators: Schorn, Safak
By far, the most unpleasant symptom of pancreatitis and pancreatic cancer is severe abdominal and/or back pain. We have recently identified the molecular, neuro-immune mediators of pain in both diseases and are currently performing pre-clinical analgesic trials for more effective pain treatment in pancreatic diseases.

Our research is funded by Deutsche Forschungsgemeinschaft (DE2428/3-1, DE2428/3-2, DE2428/6-1, SFB/CRC 1321 subproject P07), Deutsche Krebshilfe (Nr. 70112897), Wilhelm-Sander Stiftung (2015.160.1, 2019.091.1), Stiftung Chirurgie at TUM, intramural funds of the TUM, and industry.

We thank you for your interest in our research.

Ihsan Ekin Demir, MD, PhD

Principal Investigator
Pancreatic Neuropathy & Pain Research Group










Informationen in türkischer Sprache


Informationen in russischer Sprache


Experten-Ranking

Univ.-Prof. Dr. H. Friess
gehört zu den TOP 10-Experten weltweit und gilt als TOP 3 in Europa

"Rising Star"


„Rising Star“ am Rechts der Isar - Herr PD Dr. Dr. I. Ekin Demir, Facharzt für Viszeralchirurgie, wird dieses Jahr mit dem renommierten Preis „Rising Star Award“ der UEG ausgezeichnet

Einladung zum Arzt-Patiententag


Pankreas- und Darmerkrankungen

Vernissage

Herzliche Einladung zur Vernissage mit Bernd Sannwald am 30. Oktober 2019 um 18:30 Uhr

Focus Ärzteliste 2019


Die FOCUS-Gesundheit "Ärzteliste 2019" zählt Herrn Prof. Helmut Friess erneut zu Deutschlands TOP-Medizinern

Prüfung bestanden

Wir gratulieren herzlich unserer Ernährungsberaterin Frau Sabine Obermayer zur bestandenen Weiterbildung zur Diabetesassistentin...

Neue Station M1c

Patientinnen und Patienten können jetzt an der Klinik und Poliklinik für Chirurgie am Klinikum rechts der Isar der Technischen Universität München den Blick auf die Alpen oder den Ammersee genießen - vom Bett aus

Ferdinand-Sauerbruch-Forschungspreis 2018


Ferdinand-Sauerbruch-Forschungspreis 2018 wird Dr. Dr. Daniel Hartmann überreicht

Dr. Dr. Daniel Hartmann


Deutsch-afrikanische Klinikpartnerschaft


Flaggen Deutschland, Ghana

Klinikum rechts der Isar kooperiert mit Klinik in Ghana